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ORIGINAL ARTICLE
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Abstract
Background and objectives: Patients with cardiovascular disease who required to be admitted in coronary care units
(CCU) would have sleep deprivation. . During the admission some factors such as continuous ambient light exposure can
suppress melatonin release, in consequence sleep deprivation will be occurred and hinder the progress of patients'
treatment. The aim of study was to evaluate the effect of melatonin on the sleep quality of patients admitted to postCCU.
Materials and methods: This randomized clinical trial was carried out on 110 patients admitted to post-CCU at SayyadeShirazi Hospital, Gorgan, Iran. Patients with a poor sleep quality (Pittsburgh sleep quality index (PSQI) global
score>5) were randomly allocated into two intervention and placebo groups. Patients in the intervention group received
melatonin (3 mg; 30 minutes before bedtime), and the placebo group received placebo for 2 weeks, and their sleep
quality was re-evaluated after the end of intervention. Data were analyzed using paired t test, Wilcoxon, and Chi-square
tests by SPSS version 21.
Results: The results showed that mean of the patients’ PSQI scores decreased signiﬁcantly in intervention group (from
14.95 ± 1.48 to 11.65 ± 1.50, P < 0.001), while in placebo group the difference was not signiﬁcant (from 15.48 ± 1.47 to
15.24 ± 1.71, P ¼ 0.129). Post-intervention score of patients in intervention group was also lower than the placebo group
(P < 0.001).
Conclusion: The melatonin can improve the sleep quality of the patients admitted to post-CCU who suffer from sleep
disturbance.
Keywords: Melatonin, Coronary Care Units, Sleep Disorders, Heart Diseases

1. Introduction

S

leep is an important part of human's life, and
a good night sleep is critical for mental and
physical health [1], while insufﬁcient sleep can
signiﬁcantly impair the individual's quality of life
and performance [2]. Sleep disorders, deﬁned as
perceived or actual alterations in the quantity or
quality of sleep are observed in 26% of general
population [3] and over 50% of the elderly [4]. In

addition to insomnia, there are other types of
sleep disturbances, such as hypersomnia, sleeprelated breathing disorders, circadian rhythm
sleep disorders, and parasomnias [5].
Several factors are associated with sleep disturbances, such as alcohol, caffeine, and nicotine use
[6], mental disorders such as depression and anxiety
[7], and physical diseases such as diabetes, obesity,
myocardial infarction (MI), stroke, and coronary
artery disease [8]. These factors can directly cause
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sleep disorder by the inconvenience they cause
during sleep time, or indirectly by medications used
for the disease control. Hospital admission is
another factor, which can increase the risk of sleep
disturbances [9]. Accordingly, patients admitted to
coronary care unit (CCU) are reported to have a
poor quality of sleep, because of the underlying
cardiac condition, effect of medications, hospital
conditions, and stress and anxiety that they experience [10-11]. Considering that poor sleep quality is
stressful, it can stimulate the release of epinephrine
and norepinephrine, which consequently can be
associated with tachycardia, tachypnea, increased
myocardial oxygen requirements, and eventually
leads to severe ischemia and MI [12]. Therefore, it is
essential to pay attention to the sleep of the patients
admitted to CCU and post-CCU.
Pharmacological treatment options for modifying
sleep include benzodiazepines and sedating agents
(such as anxiolytics, antipsychotics, and antihistamines), which may have severe adverse effects such
as cognitive impairment [13]. Therefore, melatonin
agonists have been suggested for sleep regulation
[14]. Melatonin, one of the main hormones of pineal
gland, is secreted in response to variations in the
circadian cycle and plays a role in organization of
sleep-wake rhythm [15]. Accordingly, intravenous
and oral administration of melatonin agonists has
been suggested for sleep regulation [16]. Studies
have shown that melatonin agonists can improve
the quality of sleep in several sleep disorders,
associated with depression [17] and autism [18], as
well as primary sleep disturbances [19]. Other advantages have been also mentioned for melatonin,
such as regulation of blood pressure, immune system, and autonomic cardiovascular system, as well
as antioxidant actions [20]. Because of the poor
quality of sleep in hospital inpatients, especially
those who admitted to CCU [21-22] and lower
concentration of melatonin reported in such patients [23], we hypothesized that the use of melatonin can also improve the quality of sleep in
patients admitted to post-CCU. The aim of this
placebo-controlled randomized clinical study was to
evaluate the effect of melatonin on quality of sleep
of patients with sleep disturbance admitted to postCCU.

2. Methods
This placebo-controlled randomized clinical trial
was carried out on patients who were admitted to
post-CCU of Sayyade Shirazi Hospital, Gorgan,
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Iran. The protocol of the study was approved by the
Ethics Committee of Golestan University of Medical
Sciences (code: IR.GOUMS.REC.1396.83) and was
registered in Iranian Registry of Clinical Trials
Database (IRCT2017081010340N18). Before patient
recruitment, the researcher explained the design
and objectives of the study to the patients in person,
and asked them to sign the written informed consent form, if they were willing to participate in this
study. Considering the results of the study by Jan
and colleagues [24], a statistical power of 80%, and a
type I error of 5%, the sample size was calculated at
45 patients in each group, which was extended to 55
patients, considering 20% chance of lost to followup.
110 eligible patients who were admitted to the
post-CCU during the study period were recruited
into the study using convenient sampling method.
Inclusion criteria were poor sleep quality (Pittsburgh sleep quality index [PSQI]>5), had no physical or psychological disorder causing insomnia
such as chronic pain or mood disorders and not
using drug that regulates the sleep-wake cycle. Patients who meet the inclusion criteria were randomized into two intervention and placebo groups
in a 1:1 ratio using simple random allocation and
four-block allocation method. The placebo group
was matched in terms of age, sex, and cause of
admission with the intervention group. Then patients in both groups fulﬁll the questionnaires. The
questionnaires were administered twice to each
group; once before receiving melatonin or placebo
and once two weeks afterward. Data was gathered
using questionnaire including demographic characteristics (age, sex, ethnicity, and place of residence), clinical characteristics (cause of admission,
duration of hospital admission, and history of
admission) and PSQI. The quality of sleep was
assessed using the Persian version of PSQI, by
measuring seven subscales; subjective sleep quality
(C1), sleep latency (C2), sleep efﬁciency (C3), sleep
duration (C4), sleep disturbances (C5), use of sleep
medications (C6), and daytime dysfunction (C7)
over the last month. The patients' scores in each
subscale ranged from 0 to 3, and sleep disturbances
of the patients was categorized to no sleep disturbances (score 0), mild (score 1), moderate (score 2),
and severe sleep disturbances (score 3). The sum of
the scores in the seven subscales was considered as
the global score, ranging from 0 to 21. The reliability
of Persian version of PSQI in Iranian population was
tested previously in the study by Eliyasianfar and
colleagues by Cronbach's alpha of 0.83 [24]. The
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Fig. 1. CONSORT ﬂow diagram for study enrollment.

researcher gave sufﬁcient explanation to the participants about how to complete the questionnaire.
The patients in intervention group received 3 mg
melatonin tablets for 14 days which administered
30 minutes before bedtime, and the placebo group
received placebo for 14 days, which contained 3 mg
chickpea ﬂour that was identical with melatonin in
appearance. The drug and the placebo were produced by Mahya Darou, Iran. The placebo was
similar to the drug in terms of size, shape, and color
and was placed in sealed pockets, to mask the nurse
who gave the drugs to the patients. The researcher
who gave the questionnaire to the participants and
the analyst were also unaware of the group
allocations.
After the intervention, the researcher followed up
all the participants each 4 days and visited them in
person during their hospital admissions. After
discharge, the pills were given to the patients and
they were asked to continue taking the drug every
night routinely until 14 days after initiation of the
intervention, and they were asked to complete the
PSQI once again. Any patient who was lost to
follow-up or did not use the medication routinely
(did not take the medicine two times) was excluded
from the study.

2.1. Statistical analysis
For presenting the results, we described the frequency of qualitative variables and reported mean
and standard deviation (SD) for quantitative variables. Shapiro Wilk test was used to test the normal
distribution of the data. Comparison of numeric
variables between the groups was performed using t
test or Mann Whitney U test, whenever the data did
not appear to have normal distribution. Patients’
scores before and after the intervention were
compared using paired samples t test or its nonparametric equivalent, Wilcoxon Signed Rank test.
Categorical variables were compared using Chisquare test. For the statistical analysis, the statistical
software IBM SPSS Statistics for Windows version
21.0 (IBM Corp. 2012. Armonk, NY: IBM Corp.) was
used. P values of 0.05 or less were considered as
statistically signiﬁcant.

3. Results
Of the 110 patients enrolled into the study, 98
completed the study (Fig. 1).
There were 30 male patients (61.2%) and 19 female
patients (38.8%) in each group. Mean of the patients’
age in the intervention group was 55.04 ± 8.12 years,
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Table 1. Comparing the demographic and clinical characteristics of patients in the intervention and placebo groups.
Variables
Ethnicity

Place of residence
Cause of hospitalization
History of admission
a

Fars
Turkmen
Sistani
Baloch
Other
Urban
Rural
ACS
MI
Yes
No

Intervention N (%)

Placebo N (%)

P valuea

31 (63.27)
11 (22.45)
5 (10.20)
2 (4.08)
0 (0.0)
33 (67.3)
16 (32.7)
37 (75.5)
12 (24.5)
20 (40.8)
29 (59.2)

32 (65.31)
13 (26.53)
2 (4.08)
1 (2.04)
1 (2.04)
27 (55.1)
22 (44.9)
36 (73.5)
13 (26.5)
24 (49)
25 (51)

0.591

0.214
0.817
0.417

The results of Chi-square test. ACS: Acute coronary syndrome; MI: Myocardial infarction.

and that of the placebo group was 56.02 ± 7.08 years
(P ¼ 0.53; independent samples t test). There was no
difference between the groups in terms of ethnicity
(P ¼ 0.591), place of residence (P ¼ 0.214), cause of
hospital admission (P ¼ 0.817), and admission history (P ¼ 0.417), as shown in Table 1.
Mean of the patients’ PSQI scores decreased
signiﬁcantly in the intervention group from
14.95 ± 1.48 before the intervention to 11.65 ± 1.50
after the intervention (P < 0.001), while the change
in the placebo group was not statistically signiﬁcant
(from 15.48 ± 1.47 to 15.24 ± 1.71, P ¼ 0.129).
Furthermore, the mean score after the intervention
was signiﬁcantly lower in the intervention group

compared with the placebo group (P < 0.001),
although the baseline mean scores were not
different between the groups (P ¼ 0.079). The mean
scores in different subscales of the questionnaire are
shown in Table 2. As indicated, the mean baseline
scores were similar between the groups (P > 0.05),
except in terms of using sleep medications
(P < 0.001), while after 2 weeks, the mean scores of
the groups were signiﬁcantly different, lower in the
intervention group (P < 0.05; Table 2).
Comparing the change in each group using paired
t test showed a signiﬁcant decrease in mean scores
of all the seven subscales of PSQI, including subjective sleep quality (P < 0.001), sleep latency

Table 2. Comparing mean PSQI scores between the groups before and after the intervention.
Total score

Subjective sleep quality

Sleep latency

Sleep duration

Habitual sleep efﬁciency

Sleep disturbances

Using sleep medication

Daytime dysfunction

a
b

Intervention
Placebo
P-valuea
Intervention
Placebo
P-valuea
Intervention
Placebo
P-valuea
Intervention
Placebo
P-valuea
Intervention
Placebo
P-valuea
Intervention
Placebo
P-valuea
Intervention
Placebo
P-valuea
Intervention
Placebo
P-valuea

P-value based on independent samples t test.
P-value based on paired t test.

Before

After

Mean difference ±SD

P-valueb

14.95 ± 1.48
15.48 ± 1.47
0.079
2.20 ± 0.57
2.10 ± 0.58
0.387
1.87 ± 0.69
1.89 ± 0.62
0.879
2.02 ± 0.55
1.91 ± 0.53
0.358
2.42 ± 0.50
2.42 ± 0.50
1.00
2.26 ± 0.56
2.42 ± 0.50
0.135
2.51 ± 0.50
2.91 ± 0.27
<0.001
1.65 ± 0.69
1.81 ± 0.66
0.238

11.65 ± 1.50
15.24 ± 1.71
<0.001
0.93 ± 0.62
1.22 ± 0.62
0.026
1.44 ± 0.50
2.00 ± 0.64
<0.001
1.79 ± 0.53
2.12 ± 0.59
0.006
2.28 ± 0.50
2.59 ± 0.43
0.004
2.00 ± 0.57
2.51 ± 0.50
<0.001
1.81 ± 0.66
2.95 ± 0.19
<0.001
1.36 ± 0.66
1.80 ± 0.47
0.001

3.3 ± 1.6
0.24 ± 1.1

<0.001
0.129

1.26 ± 0.53
0.87 ± 0.56

<0.001
<0.001

0.42 ± 0.7
0.1 ± 0.46

<0.001
0.133

0.22 ± 0.42
0.2 ± 0.53

0.001
0.011

0.14 ± 0.35
0.16 ± 0.47

0.007
0.019

0.26 ± 0.49
0.08 ± 0.27

<0.001
0.044

0.69 ± 0.68
0.04 ± 0.19

<0.001
0.159

0.28 ± 0.45
0.01 ± 0.2

<0.001
0.91
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(P < 0.001), sleep duration (P ¼ 0.001), habitual sleep
efﬁciency (P ¼ 0.007), sleep disturbances (P < 0.001),
using sleep medication (P < 0.001), and daytime
dysfunction (P < 0.001) in the intervention group.
The change in the mean scores of subjective sleep
quality (P < 0.001), sleep duration (P ¼ 0.011),
habitual sleep efﬁciency (P ¼ 0.019), and sleep disturbances (P ¼ 0.044) was also signiﬁcantly different
in the placebo group, indicating decrease in subjective sleep quality and increase in the mean scores
of sleep duration, sleep efﬁciency, and disturbances.
However, the change in mean scores of sleep latency (P ¼ 0.133), using sleep medications
(P ¼ 0.159) and daytime dysfunction (P ¼ 0.91) was
not signiﬁcant in the placebo group. Studying the
association of melatonin with sleep quality based on
different variables showed a non-signiﬁcant effect of
age (P ¼ 0.771), sex (P ¼ 0.499), ethnicity (P ¼ 0.821),
cause of admission (P ¼ 0.347), and place of residence (P ¼ 0.374).

4. Discussion
The present study showed that 14 days administration of 3 mg melatonin, taken once daily, can
signiﬁcantly improve the sleep quality of patients in
post-CCU. In our study, the groups were similar
regarding mean age, ethnicity, place of residence,
cause of hospital admission, and admission history,
and the effect of melatonin in the intervention group
was not associated with the patients' demographics
or cause of admission. These results show that
melatonin could be used for improvement of sleep
quality in such patients. It has been previously
determined that endogenous melatonin acts as a
sleep regulator and its deﬁciency has been documented in patients suffering from sleep disturbance
[25]. Accordingly, exogenous melatonin has been
used as a treatment option for regulating sleep and
improving the quality of sleep [26]. Measurement of
sleep quality using PSQI in breast cancer survivors
has shown that 3 mg oral melatonin for 4 months
could signiﬁcantly improve patients' subjective
sleep quality compared with the control group [27],
which is similar to the results of the present study,
although the type of disease evaluated was different
with ours. The effectiveness of melatonin has been
also conﬁrmed in patients with other conditions,
such as chronic obstructive pulmonary disease [28],
depression [17], autism [18], schizophrenia, and
Alzheimer's disease [16], which conﬁrm the results
of our study, although the setting and study populations were different.
As patients admitted to CCU have decreased level
of melatonin [23] and have an increased risk of poor
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sleep and impaired quality and quantity of sleep
[21-22], it is important to pay attention to their sleep
pattern. Accordingly, research has focused on strategies to improve patients' sleep during their
admission. Some researchers have suggested using
eye mask and earplugs as easy and cheap methods
to be used for improving patients' sleep in those
admitted to intensive care unit (ICU) or CCU [29],
while these methods can only control the noise and
light effects affecting patients' sleep and not the
pathophysiology of the sleep disturbance [30].
Others have also suggested interventions such as
music or aromatherapy to reduce patients’ anxiety
and hence, improve their sleep quality in cardiac
patients admitted to ICU [31] and CCU [32]. On the
other hand, as patients admitted to CCU and postCCU have underlying cardiac conditions and are
taking several medications, it is not safe to prescribe
the routine sedatives to these patients, because of
the risk of adverse effects, such as respiratory suppression or change in the cardiac rhythm [33], as
well as the possible drug interactions between sedatives and other drugs the patients are taking.
Therefore, melatonin, which has been conﬁrmed as
a safe and efﬁcient sleep regulator, can be an
appropriate medication for sleep regulation in critically ill patients [34]. Huang et al. investigated the
effect of 3 mg oral melatonin, administered for
4 days, in addition to ear plugs and eye masks in
patients admitted to ICU and compared sleep
quality and polysomnography results of these patients with placebo. The results showed melatonin
as a safe, effective, and easily implementable
method for improving sleep quality in these patients
[35]. These results have been conﬁrmed in stimulated ICU environment [36-37], and melatonin has
shown favorable results in terms of sleep and
delirium of patients admitted to ICU [38]. Although
the results of these studies conﬁrmed that of ours,
regarding the effectiveness of melatonin in critically
ill patients, the questionnaire used for evaluating
the sleep quality by Huang and partners (Richards
Campbell Sleep Questionnaire) [35] was different
from that used in our study, PSQI. Furthermore,
patients admitted to ICU may have different conditions compared with patients admitted to postCCU. In another study, Bourne and colleagues
investigated the effect of 10 mg oral melatonin
compared with placebo, administered for 4 days to
critically ill patients receiving mechanical ventilation, using sleep efﬁciency index (SEI) [39]. The results of this study showed the role of melatonin in
increasing nocturnal sleep efﬁciency and suggested
inclusion of melatonin in routine care of critically ill
patients [40], which are consistent with the results of
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the present study, although the selected patients,
the administered dose, and duration differed from
that of our study. In another study on patients with
end stage renal disease undergoing dialysis, 6 weeks
administration of 3 mg melatonin compared with a
control group, in a cross over design with a 72-hour
washout period, showed that melatonin improved
total PSQI scores, subjective sleep quality, sleep
efﬁciency, and sleep duration [41], which conﬁrms
the results of the present study, although the patients selected were different. Another difference
between the results of that study and ours is that we
found signiﬁcant change in all of the seven subscales of PSQI, including subjective sleep quality,
sleep latency, sleep duration, habitual sleep efﬁciency, sleep disturbances, using sleep medication,
and daytime dysfunction, and the scores of all
subscales of PSQI decreased after intervention in
this group; while in the placebo group, the total
PSQI score was not different after 2 weeks
compared with the baseline. Considering the mean
scores of PSQI subscales in the placebo group, the
results showed that the mean scores of subjective
sleep quality decreased, while the mean scores of
sleep duration sleep efﬁciency, and disturbances
increased in this group. Considering the fact that
higher scores of PSQI shows worse sleep, the placebo group had not only no improvement in their
sleep status in the follow-up period, but also had a
worse sleep in most subscales of sleep, including
sleep duration, sleep efﬁciency, and disturbances
after 2 weeks, while in the intervention group, mean
scores of all of the subscales of PSQI decreased,
which shows the effectiveness of melatonin on every
subscale of sleep.
Our study have some limitations, including the
fact that we enrolled the patients into the study
using convenient sampling method and selected
patients from one center, which increase the chance
of bias and decrease the generalizability of the results. Furthermore, the questionnaire used in the
study, PSQI, is a self-report tool and is subject to any
bias in the personal views of the participants (subjective bias).

5. Conclusion
The results of the present study conﬁrmed the
efﬁcacy of 3 mg melatonin, administered for 14 days,
in patients with sleep disturbance admitted to postCCU, which not only improved the global PSQI
score, but also decreased the patients' sleep problem
in all of the seven subscales of sleep, measured by
this scale. Because of the signiﬁcance of sleep
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quality on patients’ health and the prevalence of
sleep disturbance in patients admitted to post-CCU,
it is suggested to include melatonin in routine care
of such patients. Future studies can shed light on the
possible adverse effects of melatonin in such patients, and its effectiveness compared with other
methods.
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